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Tuberculosis (TB) remains one of the top 10 causes of death world­
wide and is the leading cause of death from a single infectious agent. [1] 
Globally, an estimated 10 million people become infected with TB 
each year, with six countries accounting for 60% of the global TB 
burden.[1] Among these countries, South Africa (SA) has the highest 
burden of HIV co­infected cases.[1,2] In 2018, there were an estimated 
301 000 incident cases of TB in SA, compounded by 177 000 new HIV­
positive TB cases.[3] While TB mortality rates in SA have declined as 
a result of the expansion of antiretroviral therapy (ART) programmes 
to treat HIV, TB remains the leading cause of death in the country. [4,5] 
Despite estimates that TB incidence rates and mortality are decreasing, 
the current rate of decline is unlikely to meet the World Health 
Organization (WHO) End TB Strategy targets to reduce TB deaths by 
95% and TB cases by 90% before the year 2035.[2,6,7] In SA, reaching 
these targets requires a significant response from the National 
Tuberculosis Control Programme. While the programme has largely 
focused on treatment success rates, this focus fails to address upstream 
losses due to individuals not accessing TB­specific health services and 
those who remain undiagnosed with TB.[2] A better understanding of 
the TB care cascade and the utility of diagnostic screening services 
is therefore needed in order to improve TB detection processes and 
connect infected individuals with care.[8]
While effective asymptomatic testing is available for HIV 
diagnosis, point­of­care (PoC) screening tools for asymptomatic TB 
infection are not currently in use.[9,10] As a result, many individuals 
with TB are diagnosed late in the disease course despite opportunities 
for earlier detection.[1,11] Delay in the diagnosis of TB results in 
excess morbidity and mortality, particularly among HIV­infected 
individuals.[11,12] One of the reasons for the increasing difficulties in 
early detection of TB involves the changing demographics of and 
comorbidities with the disease. Although TB incidence rates are 
strongly associated with increasing age, the highest TB burden has 
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Background. South Africa (SA) faces a significant tuberculosis (TB) burden complicated by high rates of HIV­TB co­infection. In SA, 
emergency departments (EDs) play an important role in screening for TB.
Objectives. To determine the prevalence of TB in the ED and the effectiveness of the World Health Organization (WHO) TB screening tool.
Methods. This was a cross­sectional observational study, conducted in the ED at Livingstone Hospital, Port Elizabeth, from 4 June to 15 
July 2018. All patients aged >18 years and able to consent were administered the WHO TB screening questions and underwent a point­of­
care HIV test and demographic data collection. Patients were followed up for 1 year and tracked in the National Health Laboratory Service 
database to determine TB status using laboratory testing.
Results. Over the study period, 790 patients were enrolled. Overall, 121 patients (15.3%) were TB­positive, with 46 (38.0%) diagnosed 
after presenting to the ED and 75 (62.0%) with a previous TB history determined by self­report or confirmed laboratory testing. A greater 
proportion of the TB­positive patients were HIV­positive (49.6%) compared with the TB­negative population (24.8%). TB­positive 
individuals were more likely to present to the ED with a chief complaint of shortness of breath (SoB) (18.2%) compared with the TB­negative 
population (10.5%). Overall, the WHO TB screening tool had poor sensitivity (46.5%) and specificity (62.5%) for identifying TB­positive 
patients in the ED. A multiple logistic regression analysis, controlled for age and sex, showed HIV status (odds ratio (OR) 2.81; p<0.001) 
and SoB (OR 2.19; p<0.05) to be significant predictors of TB positivity. Adding positive HIV status and a presenting complaint of SoB 
increased sensitivity to 78.3%.
Conclusions. EDs in SA face a high burden of TB. While WHO screening guidelines identify some of these patients, including routine HIV 
testing in the ED could significantly affect the number of TB diagnoses made.
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shifted from older to younger populations in SA.[13,14] Among all 
patients infected with TB, 65% are co­infected with HIV, and HIV­
TB co­infection age rates are associated with the peak ages of HIV 
incidence.[1,14] Although TB incidence rates have historically been 
higher in males, recent data suggest that the incidence among HIV­
infected females has increased significantly and that the peak TB 
prevalence occurs at an earlier age in women compared with men. [15] 
As a result of these changing demographics and TB incidence 
profiles with high rates of HIV co­infection, screening for TB has 
become increasingly complicated.
In SA, the emergency department (ED) remains a safety net of 
the public healthcare system and manages a significant proportion 
of the acute healthcare burden. Much of the care provided by EDs 
is related to trauma and HIV, with the patients utilising EDs largely 
representing populations that cannot otherwise access or seek 
primary services.[16,17] The EDs in Eastern Cape Province are typically 
staffed by junior doctors or medical officers with little training in 
emergency medicine, and these departments continue to suffer 
from a lack of resources, staff and equipment.[16] Given the endemic 
burden of TB and high rates of ED use in SA, EDs have an important 
role in providing healthcare services to individuals with TB and can 
contribute to earlier detection of TB. As a result, low­cost options 
requiring little advanced training are necessary to screen for TB. 
However, significant gaps remain in terms of screening patients for 
TB throughout SA.[18]
In order to connect TB­positive patients with earlier care, EDs 
in SA must be better equipped to identify patients with TB and 
TB­associated comorbidities. The WHO has developed a screening 
questionnaire to identify patients with TB based on the patient’s 
answers to four symptom­related questions.[19] Although this tool 
can be applied easily in the ED setting and can screen asymptomatic 
individuals quickly in high­volume care facilities, its utility and 
effectiveness have yet to be evaluated.
Objectives
To assess the utility of the WHO screening tool in the ED setting and 
determine the prevalence of TB in the ED. We sought to determine 
the sensitivity of the WHO screening tool in detecting TB­positive 
cases and to develop a model to increase the utility of this tool.
Methods
This cross­sectional observational study was conducted from 4 June 
to 15 July 2018. During the study period, PoC HIV testing was 
implemented in accordance with the SA national testing guidelines 
and data were collected on patient demographics, chief complaint, 
severity of illness, medical history, ED course of care, and responses 
to the WHO TB screening tool. A detailed description of the Walter 
Sisulu Infection Screening in the Emergency Department (WISE) 
study methodology is available elsewhere.[10]
Study setting
The study was conducted in the ED of Livingstone Hospital in Port 
Elizabeth, Eastern Cape Province, SA. Livingstone Hospital is a 
tertiary­care centre providing 24­hour service 7 days a week and 
receives patients from up to 200 km away. The ED receives 100 ­ 
150 patients per day, has <50 beds, and during the study period was 
staffed by medical officers and nurses with limited formal training 
in emergency medicine. Patient medical records are kept in paper 
files, and handwritten logbooks are used as patient tracking systems. 
Laboratory tests are tracked and reported using an electronic­based 
system through the National Health Laboratory Service (NHLS).
Study procedures
All patients presenting for care in the ED during the study period who 
were aged >18 years, fully conscious and clinically stable were eligible 
for enrolment. Study staff were instructed to approach patients 
immediately after the triage process was completed, and patients 
were requested to provide consent to a PoC HIV test, collection of 
information using the WHO TB screening tool (Fig. 1), collection of 
demographic data, and follow­up using the NHLS LabTrak system.
Data on demographics and PoC HIV test status and from the 
WHO TB screening tool were collected by study staff using case 
report forms, which were then scanned and entered using intelligent 
character recognition DataFax software (Clinical DataFax Systems 
Inc., Canada) and centrally double­verified by independent data 
technicians. Patients were then traced in the NHLS LabTrak system 
for 1 year after their initial ED presentation, where data were collected 
at the end of the year on TB testing as well as other serological and 
microbiology testing.
ADULT TB SYMPTOM SCREENING  
Symptoms   
Temperature  BP  Pulse  Weight  Height  
Cough ≥2 weeks OR of any duration if HIV- positive  Yes  No  
Persistent fever >2 weeks  Yes  No  
Unexplained weight loss >1.5 kg in a month  Yes  No  
Drenching night sweats  >2 weeks  Yes  No  
MEDICAL HISTORY  
Close contact of a person with 
infectious TB  Yes  No  Unknown  
Type of index patient  DS TB  MDR/XDR TB  
Diabetes  Yes  No  Unknown  
HIV status  Positive  Negative  Unknown  
Fig. 1. The World Health Organization TB screening tool. (TB = tuberculosis; BP = blood pressure; DS = drug-sensitive; MDR = multidrug-resistant; 
XDR = extensively drug-resistant.)
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The primary outcome measure sought to determine the prevalence of 
undiagnosed TB among HIV­positive individuals. Data analysis was 
approached using a descriptive statistical method using Stata version 
15 (StataCorp, USA). The overall prevalence of TB was determined 
using NHLS testing data and patients’ self­reported history of TB 
diagnosis. The odds of positive TB status based on screening tools and 
clinical indicators was calculated using simple and multiple logistic 
regression analysis. Crude (unadjusted) and adjusted odds ratios (ORs) 
were used to examine the odds of TB infection and clinical factors.
The Johns Hopkins University School of Medicine Institutional 
Review Board (ref. no. IRB00105801), the Walter Sisulu University 
Human Research Ethics Committee (ref. no. 002/2016) and the 
University of Cape Town Human Research Ethics Committee (ref. no. 
401/2013) approved this study. All participants enrolled in the study 
provided written consent to receive a PoC HIV test and have detailed 
demographic data collected on both their reason for presentation and 
their ED course.
Results
A total of 790 patients were enrolled throughout the study period, 
of whom 121 (15.3%) were confirmed TB­positive. Of these, 46 
patients (38.0%) were diagnosed with TB within 12 months after 
presenting to the ED (i.e. had asymptomatic TB during their ED 
stay) and 75 (62.0%) had a known diagnosis of TB with a previous 
history of TB determined by self­report or confirmed laboratory 
testing up to 12 months before the study period. As shown in Table 1, 
significant differences in TB status by age category (p=0.023) and sex 
(p=0.001) were seen. A significant burden of patients aged <35 years 












<20 1 (0.8) 6 (2.3) 16 (3.9) 23 (2.9)
20 ­ 34 49 (40.5) 86 (33.3) 172 (41.8) 307 (38.9)
35 ­ 49 47 (38.8) 94 (36.4) 113 (27.5) 254 (32.1)
≥50 24 (19.8) 72 (27.9) 110 (26.8) 206 (26.1)
Sex     0.001*
Male 64 (52.9) 135 (52.3) 160 (38.9) 359 (45.4)
Female 57 (47.1) 123 (47.7) 251 (61.1) 431 (54.6)
Reason for ED visit     0.096
Medical 70 (57.8) 129 (50.0) 192 (46.7) 391 (49.5)
Trauma 51 (42.1) 129 (50.0) 219 (53.3) 399 (50.5)
Time of presentation†     0.592
In hours 47 (38.8) 104 (40.3) 178 (43.3) 329 (41.6)
After hours 74 (61.2) 154 (59.7) 233 (56.7) 461 (58.3)
Transport     0.234
Ambulance 50 (41.3) 87 (33.7) 120 (29.2) 257 (32.5)
Police 2 (1.7) 3 (1.2) 10 (2.4) 15 (1.9)  
Self­transport 69 (57.0) 167 (64.7) 280 (68.1) 516 (65.3)  
Unknown 0 1 (0.4) 1 (0.2) 2 (0.2)  
SATS     0.156
Emergency 3 (2.5) 5 (1.9) 8 (2.0) 16 (2.0)
Very urgent 14 (11.6) 17 (6.6) 21 (5.1) 52 (6.6)
Urgent 67 (55.4) 141 (54.7) 213 (51.8) 421 (53.3)
Routine 37 (30.6) 95 (36.8) 169 (41.1) 301 (38.1)
HIV status     <0.001*
Known positive 33 (36.4) 51 (19.8) 40 (9.7) 135 (17.1)
New positive 16 (13.2) 13 (5.0) 18 (4.4) 47 (5.9)  
Negative 48 (39.7) 138 (53.5) 234 (56.9) 420 (53.2)  
Unknown 13 (10.7) 56 (21.7) 119 (29.0) 188 (23.8)  
Disposition     0.184
Death 0 0 1 (0.2) 1 (0.1)
Admission 23 (19.0) 24 (9.3) 32 (7.8) 79 (10.0)
ICU admission 0 0 1 (0.2) 1 (0.1)
Emergency surgery 0 0 1 (0.2) 1 (0.1)
Transfer 25 (20.7) 55 (21.3) 77 (18.7) 157 (19.9)
Discharge 70 (57.8) 170 (65.9) 285 (69.3) 525 (66.5)
Absconded 3 (2.5) 6 (2.3) 10 (2.4) 19 (2.4)
Unknown 0 3 (1.2) 4 (1.0) 7 (0.9)
TB = tuberculosis; ED = emergency department; SATS = South African Triage Scale; ICU = intensive care unit.
*Statistically significant at the p<0.05 level.
†In hours designated as 08h00 ­ 16h00 and after hours as 16h01 ­ 07h59.
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(41.3%; n=50/121) were TB­positive compared with those who 
were TB­negative (35.6%; n=92/258). A large number of patients 
in the ED did not receive any TB testing (i.e. no TB testing during 
the ED visit or up to 1 year subsequently). Higher proportions of 
individuals aged <20 years (69.6%; n=16/23) and of females (58.2%; 
n=251/431) were not tested for TB compared with older populations 
(51.3%; n=395/767) and males (44.6%; n=160/359), despite a higher 
proportion of younger patients and males testing positive for TB.
There was no significant difference in TB prevalence by medical 
v. trauma complaints, although as expected more trauma patients 
(53.3%; n=219/411) were not tested for TB compared with medical 
patients (46.7%; n=192/411). A higher proportion of the TB­positive 
population was HIV­positive (40.5%; n=49/121) compared with the 
TB­negative population (24.8%; n=64/258).
In Table  2, we compare the characteristics of patients who were 
TB­positive (n=121). Of the 46 recent positives, 41 (89.1%) received 
testing in Port Elizabeth and 5 (10.9%) received testing outside Port 
Elizabeth. One recent positive was determined by biopsy and was 
the only case in which biopsy was used to determine TB status. 
No significant differences were found in age categories, sex, HIV 
status, or prevalence of comorbidities/co­infections when comparing 
patients recently diagnosed as TB­positive with those with a history 
of TB diagnosis.
There was limited completion of testing for additional pathogens or 
infections in the recent TB diagnosis population (Fig. 2). GeneXpert 
(82.6%; n=38/42) and Auramine O (87.0%; n=40/46) were used 
to diagnose TB more frequently than solid or liquid TB cultures 





































































   14                   31                 45                  35                 34                 38                  41                  6                  23                   8                    9
26                   11                  1                   11                  7                    8                   5                   25                  6                    3                   33
6                     4                   0                    0                    5                    0                   0                   15                 17                  35                  4
Fig. 2. Testing patterns in the recent TB-positive population (N=46). (TB = tuberculosis; TPHA = Treponema pallidum haemagglutination; HBV = hepatitis 
B virus; HCV = hepatitis C virus; HAV = hepatitis A virus.)
Table 2. Demographic characteristics of TB-positive populations
Previously positive 
(N=75), n (%)
Recent positive  
(N=46), n (%)
Total 
(N=121), n (%) p-value (χ2 test)
Age (years) 0.544
<20 1 (1.3) 0 1 (0.8)
20 ­ 34 29 (38.7) 20 (43.5) 49 (40.5)
35 ­ 49 32 (42.7) 15 (32.6) 47 (38.8)
≥50 13 (17.3) 11 (23.9) 24 (19.8)
Sex 0.211
Male 43 (57.3) 21 (45.7) 64 (52.9)
Female 32 (42.7) 25 (54.3) 57 (47.1)
HIV status 0.232
Positive 33 (44.0) 27 (58.7) 60 (49.6)
Negative 32 (42.7) 16 (34.8) 48 (39.7)
Unknown 10 (13.3) 3 (6.5) 13 (10.7)
Comorbidities/co­infection
Heart disease 1 (1.3) 1 (2.2) 2 (1.7) 0.725
Diabetes 4 (5.3) 1 (2.2) 5 (4.1) 0.397
Respiratory condition 12 (16.0) 5 (10.9) 17 (14.1) 0.430
TB = tuberculosis.
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was completed on 37 patients (80.4%) with a recent TB diagnosis. 
Additionally, creatinine tests (69.6%; n=32/46) were the tests most 
frequently ordered in conjunction with TB testing, while Treponema 
pallidum hemagglutination (TPHA) tests (2.2%; n=1/46) were the 
least frequently ordered. Tests for IgM and IgG antibodies against 
cytomegalovirus and tests for toxoplasmosis were never completed in 
the recent TB diagnosis population.
Of the 790 individuals who presented to the ED in Port Elizabeth, 
135 (17.1%) screened positive for TB using the WHO TB screening 
questions, while only 45 (5.7%) had testing­confirmed TB (Auramine 
O, TB culture, GeneXpert, pathology) (Table  3). As expected, 
TB­positive individuals presented to the ED with a chief complaint 
of shortness of breath (SoB) (18.2%; n=22/121) more often than 
the TB­negative population (10.5%; n=27/258). The WHO tool 
was effective in identifying some positive TB patients, but had poor 
sensitivity (46.5%; n=20/43) and specificity (62.5%; n=45/72).
The WHO TB screening tool with a positive response to any of 
the tool’s individual questions (cough >2 weeks, fever >2 weeks, 
weight loss >1.5 kg, drenching night sweats >2 weeks) and a positive 
HIV status were all statistically significant (p<0.001) predictors of a 
positive TB diagnosis, as reflected in Table 3. Outside of the WHO 
TB screening tool, a chief complaint of SoB was determined to be a 
significant predictor of a positive TB history (p=0.037). Interestingly, 
individual chief complaints similar to the WHO TB screening tool 
questions (i.e. cough/bloody cough, weight loss/wasting, fever/chills) 
were not significant predictors of a positive TB history.
A multiple logistic regression analysis, controlled for age and sex, 
showed HIV status (OR 2.81; p<0.001) and SoB (OR 2.19; p<0.05) 
to be independently significant predictors of TB positivity (Table 4). 
The single most significant predictor of positive TB status when 
adjusting for age and sex was found to be drenching night sweats 
for >2 weeks (OR 4.08). However, the odds of positive TB status was 
3.57 times higher when combining positive WHO TB screening and 
positive HIV status, and was only 3.13 times higher when combining 
positive WHO TB screening, positive HIV status and a complaint of 
SoB. The addition of positive HIV status and a presenting complaint 
of SoB increased sensitivity to 78.3%, although it decreased specificity 
to 36.5%.
Discussion
A high burden of TB was found in this SA ED, with a TB prevalence 
of 15.3% based on previous history determined by self­report 
and confirmed laboratory testing 1 year from the index visit. The 
most recent WHO estimate of TB prevalence in SA estimated 696 
cases per 100 000 population (0.696%), which is significantly lower 
than the prevalence in our study population.[20] Additionally, the 
2016 South Africa Demographic and Health Survey reported the 
proportion of self­reported TB in women and men to be 5% and 
6%, respectively.[21] These proportions are again much lower than 
those found in our study. SA has made notable progress in reducing 
TB prevalence and deaths and improving treatment outcomes 
for new smear­positive TB cases, but the burden of TB remains 
enormous. Strengthening case finding and the use of Xpert MTB/
RIF as a replacement for sputum smear microscopy are necessary to 
further accelerate progress towards improved TB control in SA and 
beyond.[22] The ED remains an untapped opportunity where both of 
these strategies could be applied.
Similar to other studies, a lower proportion of females were tested 
for TB compared with males.[14] Additionally, peak ages for TB 
positivity were in the 20 ­ 34­ and 35 ­ 49­year age groups, which has 
also been observed elsewhere.[13,14] Although the burden of TB in EDs 
throughout SA varies by centre, the high prevalence of TB found in this 
setting can probably be applied to other ED settings given the endemic 
burden of TB and the role of these departments in managing the 










<20 1 (14.3) 6 (85.7) 7 0.312
20 ­ 34 49 (36.3) 86 (63.7) 135 0.175
35 ­ 49 47 (33.3) 94 (66.7) 141 0.651
≥50 24 (25.0) 72 (75.0) 96 0.092
Female 57 (31.7) 123 (68.3) 180 0.918
HIV­positive 60 (48.4) 64 (51.6) 124 <0.001*
History of respiratory condition 17 (34.7) 32 (65.3) 49 0.656
Regular tobacco use 42 (38.9) 66 (61.1) 108 0.066
+ Cough >2 weeks 33 (50.0) 33 (50.0) 66 <0.001*
+ Fever >2 weeks 27 (54.0) 23 (46.0) 50 <0.001*
+ Weight loss >1.5 kg 33 (55.9) 26 (44.1) 59 <0.001*
+ Drenching night sweats >2 weeks 32 (60.4) 21 (39.6) 53 <0.001*
+ WHO TB screening 47 (51.7) 44 (48.3) 91 <0.001*
Chief complaint: SoB 22 (44.9) 27 (55.1) 49 0.037*
Chief complaint: cough/bloody cough 2 (50.0) 2 (50.0) 4 0.436
Chief complaint: fever/chills 1 (100.0) 0 (0.0) 1 0.144
Chief complaint: weight loss/wasting 0 (0.0) 0 (0.0) 0 ­
Triage RR >16/min 93 (30.7) 210 (69.3) 303 0.461
Triage temperature >37.8ºC 3 (42.9) 4 (57.1) 7 0.549
Triage systolic BP <90 mmHg 2 (50.0) 2 (50.0) 4 0.432
TB = tuberculosis; WHO = World Health Organization; SoB = shortness of breath; RR = respiratory rate;  
BP = blood pressure; No tint (white) = WHO screening tool.
*Statistically significant at the p<0.05 level.
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acute care of patients who may present later in the disease course. [23,16] 
The present study found a high number of patients with previously 
undetected TB, with 38% of the patients determined to be TB­positive 
having never received a previous TB diagnosis. Almost half (49.6%) of 
the TB­positive patients were co­infected with HIV, further supporting 
the high rates of co­infection determined elsewhere.[1,11,24]
A high percentage of HIV­infected patients presented with 
subclinical TB that was diagnosed only by screening and further 
laboratory testing, indicating a need for simultaneous screening 
for both HIV and TB on presentation to the ED.[24,25] Given this 
evidence, a positive HIV test should prompt further TB screening 
if not completed simultaneously in high­HIV/TB endemic settings. 
Evidence from this and other studies suggests that the most effective 
TB screening should be done in conjunction with HIV testing, 
especially given the development of affordable PoC HIV tests that 
can be conducted in resource­limited settings.[10,24­26] Furthermore, 
since WHO guidelines recommend that TB should be diagnosed and 
treated together with the initiation of ART, screening for TB should 
be conducted in all cases of known and incident HIV.[27] However, 
obstacles to PoC testing for HIV in EDs have been well documented, 
warranting the need to assess these barriers and their effect on PoC 
TB screening and testing.[28] The WHO has previously recommended 
a cough duration of 2 ­ 3 weeks as a symptom screen for TB, but this 
is now recognised as inadequate for HIV­associated TB, with the 
sensitivity frequently found to be <50% in HIV­positive patients.[29] 
Similar results were found in this study, with the four­question WHO 
screening tool providing an overall sensitivity of just 46.5%. These 
data and the high rates of HIV co­infection in the study population 
suggest that the WHO TB screening tool is largely inadequate in the 
setting of endemic HIV co­infection.
Although the WHO screening questions have been developed as 
a low­cost screening option requiring minimal advanced training to 
administer, the present study demonstrates that this tool has limited 
efficacy in its current form. The assessment of the WHO screening 
questionnaire in this study reveals the inadequacy of non­serological 
tools in detecting subclinical cases of TB, particularly in the setting 
of endemic HIV co­infection. With the modifications of the tool 
applied in our model, adding HIV status and a chief complaint of SoB 
to the four questions already included in the screening questionnaire 
substantially increased the sensitivity of the screening tool to 78.3%. 
Given the availability of low­cost PoC HIV testing in SA, this should 
be conducted together with TB screening in order to increase the 
efficacy of these efforts. Modifying the WHO screening tool in this 
way not only improves its ability to detect TB­positive patients, but 
also provides a low­cost option to detect TB more reliably in EDs 
that face a high burden of the disease. However, more importantly, 
this study provides a use case for PoC TB testing in the ED. While 
the WHO screening strategy may allow health facilities to more 
appropriately identify candidates for PoC Xpert MTB/RIF testing, 
without PoC testing many ED patients are unlikely to receive the 
follow­up care they require. The 2011 FIND study was a multicentre 
feasibility and accuracy study evaluating the implementation of Xpert 
MTB/RIF testing, and included a Ugandan ED as one of the clinical 
sites.[30] A recent multicountry southern African study demonstrated 
that not only did this PoC strategy increase treatment initiation, but 
it was also cost­effective when compared with current standard­of­
care testing strategies.[31] Our study provides further evidence that 
given the high prevalence of TB and HIV, the ED is a viable and 
necessary venue to implement PoC TB testing if we are to achieve 
epidemiological control.
Study limitations
Owing to its design as a secondary data analysis, several factors 
limited this study in terms of data collection. Many patients were 
excluded from analysis because they could not be matched to hospital 
records or were not found in the NHLS database. Furthermore, 
because no confirmatory laboratory testing was completed in a large 
number of patients, the comparison groups were greatly reduced 
for assessing the effectiveness of the WHO TB screening tool. Some 
patients may have been diagnosed using chest radiographs, PoC 
focused assessment with ultrasonography for HIV, or PoC urinary 
lipoarabinomannan assay, and these data would not be reflected in 
the NHLS database. Further assessment is also needed to determine 
barriers to PoC TB testing in the ED setting.
Conclusions
Emergency centres in SA continue to face a high burden of TB. While 
WHO screening guidelines identify some of these patients, modifying 
these guidelines and including routine HIV testing in the ED could 
signi ficantly affect the number of TB diagnoses made by increasing the 
sensitivity of this tool.
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Table 4. Odds of a positive TB diagnosis by WHO screening criteria, HIV status and SoB
                       Unadjusted Adjusted†
OR 95% CI p-value OR 95% CI p-value
HIV status 2.69 1.66 ­ 4.36 <0.001* 2.81 1.72 ­ 4.59 <0.001*
WHO cough >2 weeks 2.58 1.50 ­ 4.46 0.001* 2.65 1.53 ­ 4.60 0.001*
WHO fever >2 weeks 2.96 1.61 ­ 5.44 <0.001* 2.94 1.60 ­ 5.41 0.001*
WHO weight loss >1.5 kg 3.37 1.90 ­ 5.99 <0.001* 3.39 1.91 ­ 6.04 <0.001*
WHO drenching night sweats >2 weeks 4.12 2.25 ­ 7.56 <0.001* 4.08 2.22 ­ 7.49 <0.001*
WHO screen positive 3.13 1.91 ­ 5.13 <0.001* 3.21 1.95 ­ 5.29 <0.001*
WHO + HIV status 3.51 2.21 ­ 5.58 <0.001* 3.57 2.24 ­ 5.71 <0.001*
WHO + HIV status + SoB 2.97 1.87 ­ 4.71 <0.001* 3.13 1.96 ­ 5.01 <0.001*
Chief complaint: SoB 1.90 1.03 ­ 3.50 0.039* 2.19 1.16 ­ 4.11 0.015*
TB = tuberculosis; WHO = World Health Organization; SoB = shortness of breath; OR = odds ratio; CI = confidence interval; No tint (white) = variables increasing WHO screening tool 
sensitivity with multiple regression analysis.
*Statistically significant at the p<0.05 level.
†Adjusted for age and sex.
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